Daniel Jones
Family Medicine · Niles, MINPI 1457389264
Payments from drug & device makers
Across 388 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$676
- AbbVie$660
- Lilly USA, LLC$615
- GSK$562
- Novo Nordisk$558
- Boehringer Ingelheim$417
- plus $3K from 43 others
What the payments were for
- Food & beverage$6,731100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$264
How this compares
$6,738 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $106,717 |
| TrulicityDulaglutide | 50 | $74,300 |
| EliquisApixaban | 60 | $70,869 |
| JardianceEmpagliflozin | 46 | $69,332 |
| OzempicSemaglutide | 32 | $52,856 |
| FarxigaDapagliflozin Propanediol | 24 | $35,402 |
| JanuviaSitagliptin Phosphate | 19 | $31,701 |
| LinzessLinaclotide | 16 | $25,168 |
| MyrbetriqMirabegron | 28 | $23,106 |
| XareltoRivaroxaban | 19 | $19,612 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $19,556 |
| MounjaroTirzepatide | 12 | $16,004 |
| VraylarCariprazine Hcl | 11 | $14,949 |
| TrintellixVortioxetine Hydrobromide | 22 | $12,233 |
| Repatha SureclickEvolocumab | 11 | $5,873 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $562 | $106,71784 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $615 | $90,30462 claims |
| PfizerEliquis | $94 | $70,86960 claims |
| Boehringer IngelheimJardiance | $417 | $69,33246 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $300 | $54,95838 claims |
| Novo NordiskOzempic, Novolog | $558 | $53,67544 claims |
| AbbVieLinzess, Vraylar | $660 | $40,11727 claims |
| MerckJanuvia | $325 | $31,70119 claims |
| Astellas Pharma US IncMyrbetriq | $147 | $23,10628 claims |
| Johnson & JohnsonXarelto | $67 | $19,61219 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $125 | $12,23322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Niles
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.